---
title: "Gastrointestinal Surgery"
order: 4
category: "General Surgery"
---

# Gastrointestinal Surgery

## Overview

Gastrointestinal surgery encompasses operative procedures on the digestive tract, including colorectal surgery and bariatric surgery. These procedures address both benign and malignant conditions affecting the colon, rectum, and obesity-related metabolic disease. Modern approaches emphasize minimally invasive techniques and enhanced recovery protocols.

## Colorectal Cancer Surgery

### Indications

#### Colon Cancer

**Epidemiology**
- **Third Most Common Cancer**: In both men and women
- **Lifetime Risk**: ~4-5% in average-risk individuals
- **Screening**: Colonoscopy starting at age 45 (ACS) or 50 (USPSTF)
- **Risk Factors**: Age, family history, IBD, hereditary syndromes (Lynch, FAP)

**Clinical Presentation**
- **Right-Sided Cancers**: Anemia, occult bleeding, palpable mass, weight loss
- **Left-Sided Cancers**: Change in bowel habits, hematochezia, obstruction
- **Advanced Disease**: Abdominal pain, weight loss, ascites
- **Screening-Detected**: Most common in current era (asymptomatic)

**Diagnostic Workup**
- **Colonoscopy**: Complete examination to rectum, biopsy confirmation
- **Synchronous Lesions**: 3-5% have second primary cancer
- **Polyp Removal**: All visible polyps removed or tattooed
- **Tumor Localization**: Endoscopic tattoo (if not obvious landmark)

**Staging (AJCC 8th Edition TNM)**

**Primary Tumor (T)**
- **Tis**: Carcinoma in situ (intramucosal)
- **T1**: Invades submucosa
- **T2**: Invades muscularis propria
- **T3**: Invades through muscularis into subserosa or pericolic fat
- **T4a**: Penetrates visceral peritoneum
- **T4b**: Invades adjacent organs or structures

**Regional Lymph Nodes (N)**
- **N0**: No regional lymph node metastasis
- **N1**: 1-3 regional lymph nodes positive
  - **N1a**: 1 node
  - **N1b**: 2-3 nodes
  - **N1c**: Tumor deposits without lymph nodes
- **N2**: ≥4 regional lymph nodes positive
  - **N2a**: 4-6 nodes
  - **N2b**: ≥7 nodes

**Distant Metastasis (M)**
- **M0**: No distant metastasis
- **M1a**: One organ/site
- **M1b**: More than one organ/site
- **M1c**: Peritoneal metastasis

**Stage Grouping**
- **Stage 0**: Tis N0 M0
- **Stage I**: T1-2 N0 M0
- **Stage IIA**: T3 N0 M0
- **Stage IIB**: T4a N0 M0
- **Stage IIC**: T4b N0 M0
- **Stage IIIA**: T1-2 N1 M0, T1 N2a M0
- **Stage IIIB**: T3-4a N1 M0, T2-3 N2a M0, T1-2 N2b M0
- **Stage IIIC**: T4a N2a M0, T3-4a N2b M0, T4b N1-2 M0
- **Stage IV**: Any T Any N M1

#### Rectal Cancer

**Definition**
- Tumor within 15 cm from anal verge
- **Low**: <5 cm from anal verge
- **Mid**: 5-10 cm
- **High**: 10-15 cm

**Unique Considerations**
- **Total Mesorectal Excision (TME)**: Critical for oncologic outcomes
- **Sphincter Preservation**: Balance oncology and function
- **Neoadjuvant Therapy**: Standard for T3+, node-positive disease
- **Lateral Pelvic Nodes**: May require extended dissection

**Additional Staging**
- **Pelvic MRI**: Gold standard for rectal cancer staging
  - Depth of invasion
  - Mesorectal fascia involvement
  - Lymph node assessment
  - Sphincter involvement
- **Endorectal Ultrasound**: Early-stage disease (T1-2), complementary to MRI

### Preoperative Assessment

#### Clinical Evaluation
- **Complete History**: Symptoms, duration, weight loss, family history
- **Physical Examination**: Abdominal examination, digital rectal exam (rectal cancer)
- **Performance Status**: ECOG, ASA classification
- **Comorbidities**: Cardiovascular, pulmonary, renal disease

#### Laboratory Studies
- **Complete Blood Count**: Assess anemia
- **Comprehensive Metabolic Panel**: Liver function, renal function
- **CEA (Carcinoembryonic Antigen)**: Baseline (prognostic, surveillance marker)
- **Tumor Markers**: Not diagnostic but useful for monitoring

#### Imaging Studies

**Staging Workup**
- **Chest CT**: Pulmonary metastases
- **Abdomen/Pelvis CT with IV Contrast**:
  - Primary tumor assessment
  - Lymphadenopathy
  - Liver metastases
  - Adjacent organ invasion
- **PET-CT**: Selected cases (questionable metastases, recurrent disease)

**Rectal Cancer-Specific**
- **Pelvic MRI with Rectal Protocol**:
  - T-stage accuracy >85%
  - Mesorectal fascia relationship (CRM - circumferential resection margin)
  - Extramural vascular invasion (EMVI)
  - Lymph node status

#### Risk Stratification

**High-Risk Features (Consider Neoadjuvant Therapy)**
- **Colon**: T4b, perforation, obstruction, positive margins anticipated
- **Rectal**: T3-4, node-positive, threatened CRM (<2 mm)

**Hereditary Syndromes Screening**
- **Lynch Syndrome**: MSI testing, immunohistochemistry (MLH1, MSH2, MSH6, PMS2)
- **FAP**: APC gene testing if multiple polyps

#### Optimization
- **Nutritional Assessment**: Albumin, prealbumin, weight loss >10%
- **Prehabilitation**: Exercise, nutrition, smoking cessation
- **Cardiopulmonary Optimization**: Especially for major resections
- **Bowel Preparation**: Controversial, see below

### Surgical Techniques

#### Principles of Oncologic Resection

**Adequate Margins**
- **Proximal/Distal**: 5 cm for colon, 2 cm for rectum (can be <1 cm for low rectal with neoadjuvant therapy)
- **Radial Margin**: Wide mesenteric excision

**Lymphadenectomy**
- **Minimum**: 12 lymph nodes for adequate staging
- **High Ligation**: Vessels ligated at origin (e.g., IMA for left colon)
- **Complete Mesocolic Excision (CME)**: Embryologic planes, entire mesocolon

**Total Mesorectal Excision (TME)** (Rectal Cancer)
- **Critical Technique**: Precise dissection in areolar plane between mesorectal fascia and parietal fascia
- **Sharp Dissection**: Under direct vision
- **Intact Mesorectum**: "Tumor-specific mesenteric excision"
- **Nerve Preservation**: Hypogastric nerves (sympathetic), pelvic plexus (parasympathetic)

#### Right Hemicolectomy

**Indications**
- Cecal cancer
- Ascending colon cancer
- Hepatic flexure cancer
- Proximal transverse colon cancer

**Technique (Laparoscopic/Open)**

**Patient Positioning**
- Supine, arms tucked
- Slight Trendelenburg and left tilt

**Port Placement** (Laparoscopic)
- Umbilical (camera)
- RLQ working port
- Suprapubic working port
- LUQ/LLQ retraction ports

**Operative Steps**
1. **Diagnostic Laparoscopy**: Assess tumor, metastases, resectability
2. **Medial-to-Lateral Approach** (Preferred):
   - Identify ileocolic vessels
   - Score peritoneum medial to vessels
   - Ligate ileocolic vessels at origin
   - Continue along SMV/SMA plane
   - Ligate right colic and right branch of middle colic (if present)
3. **Lateral Mobilization**:
   - Divide white line of Toldt
   - Mobilize right colon and hepatic flexure
4. **Duodenal Mobilization**: Complete hepatic flexure takedown
5. **Terminal Ileum Division**:
   - 5-10 cm proximal to ileocecal valve
   - Stapled division
6. **Transverse Colon Division**:
   - Mid-transverse or proximal depending on tumor location
   - Ensure adequate margin and blood supply to remaining colon
7. **Specimen Extraction**: Extraction site (often extend umbilical port)
8. **Ileocolic Anastomosis**:
   - **Extracorporeal**: Bring ileum and transverse colon through extraction site
   - **Intracorporeal**: Stapled or hand-sewn within abdomen
   - Techniques: Side-to-side, end-to-side, end-to-end
9. **Mesenteric Closure**: Close mesenteric defect
10. **Final Inspection**: Hemostasis, anastomotic integrity

**CME Technique**
- High ligation of ileocolic, right colic, right branch middle colic
- Dissection along embryologic planes
- Complete removal of mesocolon to fascia

#### Left Hemicolectomy

**Indications**
- Descending colon cancer
- Splenic flexure cancer

**Technique**
- **Similar Principles**: Medial-to-lateral or lateral-to-medial
- **Vascular Ligation**: Left colic artery (high ligation vs. preservation debated)
- **Splenic Flexure Mobilization**: Complete mobilization
- **Anastomosis**: Transverse colon to sigmoid/descending colon

#### Sigmoid Colectomy

**Indications**
- Sigmoid colon cancer
- Diverticular disease (not discussed here)

**Technique**
- **Vascular Ligation**: IMA (high ligation) or sigmoid/superior rectal arteries (low ligation)
  - **High Ligation**: At IMA origin, maximum lymphadenectomy
  - **Low Ligation**: Preserves left colic artery, may improve blood supply to anastomosis
- **Proximal Margin**: Descending colon
- **Distal Margin**: Rectum (well-vascularized sigmoid for anastomosis)
- **Splenic Flexure**: Mobilization controversial, based on tension/blood supply

#### Anterior Resection (High/Low)

**Indications**
- High, mid, or low rectal cancer with adequate distal margin for sphincter preservation

**Technique**

**High Anterior Resection** (Upper rectum)
- Similar to sigmoid colectomy
- Distal margin in upper/mid rectum
- Colorectal anastomosis

**Low Anterior Resection** (Low rectum)
- **TME Critical**: See principles above
- **Mobilization**: Complete rectal mobilization to pelvic floor
- **Distal Margin**: 1-2 cm (oncologically adequate if negative margin, especially post-neoadjuvant)
- **Anastomosis**: Colorectal or coloanal
  - Circular stapled (EEA) most common
  - Hand-sewn coloanal if very low
- **Diverting Loop Ileostomy**: Protective, especially for low anastomoses

**TME Steps**
1. **High Ligation**: IMA
2. **Posterior Dissection**: Presacral space, "holy plane"
3. **Lateral Dissection**: Along pelvic sidewalls, preserve autonomic nerves
4. **Anterior Dissection**:
   - Males: Denonvilliers' fascia (between rectum and prostate/seminal vesicles)
   - Females: Between rectum and vagina
5. **Distal Division**: Adequate margin
6. **Specimen Removal**: Intact mesorectum, quality assessment (complete, nearly complete, incomplete)

#### Abdominoperineal Resection (APR)

**Indications**
- Very low rectal cancer (<5 cm from anal verge)
- Involving anal sphincter complex
- Patient factors precluding anastomosis

**Technique**
- **Abdominal Phase**: TME as described above
- **Perineal Phase**:
  - Prone or lithotomy position
  - Circumferential incision around anus
  - Dissection through ischiorectal fossa
  - Meet abdominal dissection
  - Remove rectum and anus en bloc
- **End Colostomy**: Left lower quadrant
- **Pelvic Floor Closure**: Primary or with flap

**Complications**
- **Perineal Wound**: High infection/dehiscence rate (30-50%)
- **Sexual/Urinary Dysfunction**: Higher than LAR
- **Permanent Colostomy**: Quality of life impact

#### Laparoscopic vs. Open vs. Robotic

**Laparoscopic**
- **Advantages**: Less pain, faster recovery, shorter hospital stay, equivalent oncologic outcomes
- **Trials**: COST, COLOR, CLASICC trials show equivalence
- **Rectal**: May have better visualization in pelvis
- **Learning Curve**: Significant, especially for rectal

**Robotic**
- **Advantages**: 3D visualization, wristed instruments, stable camera
- **Rectal Cancer**: May facilitate TME in narrow pelvis
- **Cost**: Higher operative cost
- **Evidence**: Non-inferiority to laparoscopic, potential benefits in complex cases

**Open**
- **Indications**: Emergency (obstruction, perforation), locally advanced, extensive adhesions, conversion from laparoscopic
- **Outcomes**: Equivalent oncologic outcomes to laparoscopic

### Postoperative Management

#### Enhanced Recovery After Surgery (ERAS) Protocol

**Preoperative**
- **No Prolonged Fasting**: Clear liquids up to 2 hours preop
- **Carbohydrate Loading**: Night before and morning of surgery
- **No Bowel Prep**: Not routine (see controversy below)
- **Antibiotic Prophylaxis**: Cefazolin + metronidazole or alternative

**Intraoperative**
- **Goal-Directed Fluid Therapy**: Avoid fluid overload
- **Normothermia**: Maintain body temperature
- **Multimodal Analgesia**: Minimize opioids
- **Short-Acting Anesthetics**

**Postoperative**
- **Early Mobilization**: Out of bed POD 0 or 1
- **Early Oral Intake**: Clear liquids POD 0, advance as tolerated
- **Multimodal Analgesia**: NSAIDs, acetaminophen, TAP blocks, minimize opioids
- **DVT Prophylaxis**: Sequential compression devices, heparin
- **Avoid Routine NG Tubes**: Unless high-output or ileus
- **Remove Foley**: POD 1-2 (unless low pelvic dissection)

**Outcomes with ERAS**
- Reduced hospital stay (2-4 days vs. 5-7 days)
- Lower complications
- Faster return of bowel function
- High patient satisfaction

#### Bowel Preparation Controversy

**Traditional Approach**: Mechanical bowel prep (MBP) ± oral antibiotics

**Current Evidence**
- **MBP Alone**: No benefit, may increase complications
- **Oral Antibiotics Alone** or **MBP + Oral Antibiotics**:
  - Reduces surgical site infections
  - Reduces anastomotic leak (some studies)
  - Recommended by many (e.g., neomycin + erythromycin or metronidazole)

**Practice Patterns**: Variable, trend toward oral antibiotics ± MBP

#### Diet Advancement
- **ERAS**: Early feeding (clear liquids POD 0, regular diet POD 1)
- **Traditional**: Wait for bowel function (flatus, bowel movement)
- **Evidence**: Early feeding safe, may speed recovery

#### Drain Management
- **Pelvic Drains**: Consider for low pelvic dissections, remove when output low
- **Routine Drains**: Not indicated for most colectomies

#### Stoma Care (If applicable)
- **Stoma Nurse Education**: Preoperative and postoperative
- **Support Groups**: Ostomy support
- **Complications**: Monitor for ischemia, retraction, stenosis, hernia

### Complications

#### Anastomotic Leak

**Incidence**
- **Colon**: 2-5%
- **Rectal**: 5-15% (higher for low anastomoses)

**Risk Factors**
- Low anastomosis
- Male gender
- Smoking, obesity
- Steroid use
- Poor blood supply
- Tension on anastomosis

**Presentation**
- **Early** (3-7 days): Fever, tachycardia, abdominal pain, peritonitis
- **Late**: Pelvic abscess, fistula
- **Subtle**: Prolonged ileus, unexplained leukocytosis

**Diagnosis**
- **Clinical Suspicion**: Low threshold
- **CT Scan**: Extraluminal air, fluid collection, oral contrast extravasation
- **Water-Soluble Contrast Enema**: If CT equivocal

**Management**
- **Small, Contained**: Antibiotics, bowel rest, percutaneous drainage
- **Large, Free Perforation**: Urgent reoperation
  - Take down anastomosis
  - End ostomy (Hartmann's or loop ileostomy)
  - Washout
- **Diverting Ostomy**: If not already present, may suffice for small leaks

**Prevention**
- **Adequate Blood Supply**: Preserve marginal artery
- **Tension-Free Anastomosis**: Adequate mobilization
- **Protective Ostomy**: Low pelvic anastomoses
- **Intraoperative Leak Test**: Air or methylene blue test

#### Ileus vs. Small Bowel Obstruction

**Postoperative Ileus** (Expected, resolves)
- Normal physiologic response
- Duration: 3-5 days typical
- Management: Supportive (NPO, NG if vomiting, fluids, electrolytes)

**Small Bowel Obstruction** (Pathologic)
- Mechanical obstruction
- Causes: Adhesions, internal hernia, herniation at port site
- Imaging: Transition point on CT
- Management: Conservative initially, surgery if persistent or complete

#### Bleeding
- **Intra-abdominal**: Mesenteric vessels, splenic injury, trocar sites
- **Anastomotic**: Early or late
- **Management**: Resuscitation, may need reoperation

#### Surgical Site Infection (SSI)

**Incidence**: 10-25% (clean-contaminated)

**Risk Factors**: Contamination, obesity, diabetes, long operative time

**Management**
- **Superficial**: Open, pack, local care
- **Deep/Organ-Space**: Antibiotics, drainage (CT-guided or operative)

**Prevention**
- Antibiotic prophylaxis
- Skin preparation
- Oral antibiotics (preop)
- Wound protector during extraction

#### Urinary/Sexual Dysfunction (Rectal Surgery)

**Incidence**: 10-40% (varies by extent of dissection)

**Etiology**: Autonomic nerve injury (hypogastric, pelvic plexus)

**Presentation**
- **Urinary**: Retention, incontinence
- **Sexual**: Erectile dysfunction (males), dyspareunia (females), retrograde ejaculation

**Prevention**
- **TME with Nerve Preservation**: Stay in correct plane
- **Identification**: Recognize autonomic nerves

**Management**
- **Urinary Retention**: Catheter, alpha-blockers, may resolve over weeks
- **Sexual Dysfunction**: Counseling, PDE5 inhibitors (males), time (some recovery possible)

### Outcomes

#### Oncologic Outcomes

**Stage-Specific 5-Year Survival**
- **Stage I**: 90-95%
- **Stage II**: 80-85%
- **Stage IIIA**: 75-80%
- **Stage IIIB**: 60-70%
- **Stage IIIC**: 40-50%
- **Stage IV**: 10-15% (resectable metastases may have better outcomes)

**Local Recurrence**
- **Colon**: <5% with adequate resection
- **Rectal (with TME)**: 5-10% (vs. 20-30% pre-TME era)

**Adjuvant Chemotherapy**
- **Stage III**: Standard (FOLFOX, CapeOx)
- **Stage II**: High-risk features (T4, perforation, <12 nodes, etc.)

#### Functional Outcomes

**Bowel Function**
- **Right Hemicolectomy**: Loose stools initially, improves over months
- **Left Hemicolectomy**: Usually minimal change
- **Low Anterior Resection**: LARS (Low Anterior Resection Syndrome)
  - Frequency, urgency, fragmentation, incontinence
  - 30-60% experience symptoms
  - Improves over 12-24 months but may persist

**Quality of Life**
- **Laparoscopic**: Faster return to baseline
- **Permanent Stoma**: Adjustment period, support important
- **Sexual/Urinary**: Significant impact if dysfunction occurs

## Bariatric Surgery

### Indications

#### Obesity Definitions
- **Class I**: BMI 30-34.9 kg/m²
- **Class II**: BMI 35-39.9 kg/m²
- **Class III** (Severe): BMI ≥40 kg/m²

#### Metabolic Surgery Indications (ASMBS/IFSO Guidelines)

**Primary Indications**
- **BMI ≥40 kg/m²** (or ≥37.5 kg/m² in Asian populations)
- **BMI ≥35 kg/m²** with one or more obesity-related comorbidities:
  - Type 2 diabetes mellitus
  - Hypertension
  - Obstructive sleep apnea
  - Nonalcoholic fatty liver disease/steatohepatitis
  - Dyslipidemia
  - Cardiovascular disease
  - Osteoarthritis

**Expanded Indications**
- **BMI 30-34.9 kg/m²** with poorly controlled type 2 diabetes despite optimal medical therapy

**Age**
- Adults (≥18 years)
- Adolescents with severe obesity and comorbidities (selected cases)
- Older adults (>65) with appropriate risk stratification

### Preoperative Assessment

#### Multidisciplinary Evaluation

**Surgical**
- Obesity history, previous weight loss attempts
- Comorbidities assessment
- Anatomic considerations
- Informed consent (risks, benefits, expectations)

**Medical**
- Cardiovascular risk assessment
- Endocrine evaluation (diabetes, thyroid)
- Pulmonary function (if OSA or obesity hypoventilation)
- Liver disease assessment (NASH)

**Nutritional**
- Dietary assessment and counseling
- Vitamin/mineral deficiencies (correct preoperatively)
- Nutritional goals and expectations

**Psychological**
- Eating disorder screening
- Depression/anxiety assessment
- Motivation and realistic expectations
- Substance abuse screening

**Insurance Requirements**
- Often require 6-month medically supervised weight loss
- Documentation of comorbidities
- Psychological clearance

#### Laboratory Studies
- **Metabolic Panel**: Baseline renal, liver function
- **Hemoglobin A1c**: Diabetes assessment
- **Lipid Panel**: Dyslipidemia
- **Vitamin Levels**: B12, folate, vitamin D, iron studies, thiamine
- **Thyroid Function**: TSH
- **Pregnancy Test**: Women of childbearing age

#### Imaging/Diagnostic Studies
- **Upper GI Series** or **EGD**: Assess anatomy, hiatal hernia, ulcers
- **Abdominal Ultrasound**: Gallstones (if present, consider concurrent cholecystectomy)
- **Sleep Study**: If OSA symptoms

#### Optimization
- **Weight Loss**: 5-10% preoperative weight loss improves outcomes
- **Smoking Cessation**: Mandatory (at least 6 weeks preop)
- **Diabetes Control**: Optimize glycemic control
- **Sleep Apnea**: CPAP compliance
- **Nutrition**: Protein supplementation, vitamin repletion

### Surgical Techniques

#### Sleeve Gastrectomy (SG)

**Overview**
- **Most Common**: 60-70% of bariatric procedures in US
- **Mechanism**: Restrictive + hormonal (decreased ghrelin)
- **Technique**: Vertical gastrectomy along greater curvature

**Operative Technique** (Laparoscopic)

**Patient Positioning**
- Supine, split-leg or legs together
- Reverse Trendelenburg

**Port Placement**
- 5 ports (5-12 mm)
- Liver retractor for left lobe exposure

**Steps**
1. **Mobilization of Greater Curvature**:
   - Divide gastrocolic ligament
   - Start 3-6 cm proximal to pylorus (preserve antrum vs. aggressive resection debated)
   - Continue to angle of His
   - Completely mobilize fundus

2. **Identification of Landmarks**:
   - Pylorus
   - Incisura angularis
   - Gastroesophageal junction

3. **Bougie Placement**:
   - 32-40 French bougie inserted by anesthesia
   - Positioned along lesser curvature

4. **Stapled Gastrectomy**:
   - Start 3-6 cm from pylorus
   - Fire staplers vertically along bougie
   - Continue to angle of His
   - Ensure removal of entire fundus
   - Typical: 6-8 staple loads

5. **Specimen Removal**:
   - Extract stomach through largest port site

6. **Staple Line Reinforcement** (Controversial):
   - Oversewing, buttressing, or imbrication
   - Reduces bleeding, leak (debated)

7. **Leak Test**:
   - Methylene blue or air insufflation
   - Ensure no leaks

8. **Final Inspection**: Hemostasis

**Technical Considerations**
- **Bougie Size**: Affects restriction (smaller = more restrictive, higher complication risk)
- **Distance from Pylorus**: Affects emptying and restriction
- **Fundus**: Complete excision critical (reduces reflux, ensures weight loss)

#### Roux-en-Y Gastric Bypass (RYGB)

**Overview**
- **"Gold Standard"**: Longest track record
- **Mechanism**: Restrictive + malabsorptive + hormonal
- **Technique**: Small gastric pouch, Roux-en-Y reconstruction

**Operative Technique** (Laparoscopic)

**Port Placement**
- 5-6 ports
- Liver retractor

**Steps**
1. **Creation of Gastric Pouch** (15-30 mL):
   - Divide stomach horizontally below GE junction
   - Create small proximal pouch
   - Ensure no acid-producing parietal cells in pouch

2. **Division of Jejunum**:
   - 30-50 cm distal to ligament of Treitz
   - Biliopancreatic limb (proximal)
   - Roux limb (distal)

3. **Roux Limb Creation**:
   - Measure Roux limb (typically 75-150 cm)
   - Bring Roux limb to gastric pouch
   - **Antecolic** or **Retrocolic** (through transverse mesocolon)

4. **Gastrojejunostomy**:
   - Anastomose Roux limb to gastric pouch
   - **Circular Stapled**, **Linear Stapled**, or **Hand-Sewn**
   - Small diameter (10-12 mm) for restriction

5. **Jejunojejunostomy**:
   - Anastomose biliopancreatic limb to Roux limb
   - Side-to-side stapled or hand-sewn
   - Close mesenteric defects (prevent internal hernia)

6. **Leak Testing**: Methylene blue, endoscopy, or air

7. **Drain Placement**: Optional, near gastrojejunostomy

**Limb Lengths**
- **Standard**: Roux 75-150 cm, biliopancreatic 30-50 cm
- **Longer Limb**: More malabsorption, greater weight loss, more nutritional deficiencies

#### Adjustable Gastric Banding (AGB)

**Overview**
- **Declining Use**: <1% of bariatric procedures
- **Mechanism**: Restrictive only
- **Technique**: Inflatable band around proximal stomach

**Reasons for Decline**
- Lower weight loss
- High reoperation rate (30-50%)
- Complications: Band erosion, slippage, port issues
- Inadequate diabetes resolution

**Currently Used**: Primarily outside US

#### Biliopancreatic Diversion with Duodenal Switch (BPD/DS)

**Overview**
- **Most Complex**: Highest malabsorption
- **Indications**: Super-obesity (BMI >50), revision of failed procedures
- **Mechanism**: Restrictive + significant malabsorption

**Technique**
- Sleeve gastrectomy
- Duodenal transection
- Long Roux limb (150-250 cm)
- Short common channel (50-100 cm)

**Outcomes**
- Greatest weight loss
- Highest nutritional deficiency risk
- Loose stools/diarrhea common

#### Single Anastomosis Duodenal-Ileal Bypass with Sleeve Gastrectomy (SADI-S)

**Overview**
- **Simplified BPD/DS**: Single anastomosis
- **Increasing Popularity**: Easier than traditional BPD/DS

**Technique**
- Sleeve gastrectomy
- Duodenal transection
- Duodenoileal anastomosis (200-300 cm from ileocecal valve)

### Postoperative Management

#### Immediate Postoperative Care

**Hospital Stay**
- **Sleeve, RYGB**: 1-2 days
- **BPD/DS**: 2-3 days

**Early Mobilization**
- Out of bed POD 0
- Ambulate frequently

**DVT Prophylaxis**
- **Critical**: High risk population
- Sequential compression devices
- Heparin (LMWH or unfractionated)
- Early and frequent ambulation

**Leak Evaluation**
- **Upper GI Series** (POD 1): Some programs
- **Clinical Vigilance**: Tachycardia (>120) may be only sign of leak

#### Diet Progression

**Standard Progression**
- **POD 0-1**: Clear liquids, sips only
- **Weeks 1-2**: Full liquids (protein shakes)
- **Weeks 3-4**: Pureed foods
- **Weeks 5-6**: Soft foods
- **Week 7+**: Regular diet (small portions, protein first)

**Dietary Guidelines**
- **Small Portions**: 2-4 oz per meal initially
- **Protein First**: 60-80 g protein daily
- **Avoid Liquids with Meals**: Wait 30 minutes before/after
- **Slow Eating**: Chew thoroughly
- **Avoid High-Calorie Liquids**: No sugary drinks (dumping syndrome with RYGB)

#### Vitamin/Mineral Supplementation (Lifelong)

**All Procedures**
- **Multivitamin**: Twice daily
- **Calcium Citrate**: 1200-1500 mg/day (in divided doses)
- **Vitamin D**: 3000 IU/day (minimum)
- **Vitamin B12**: 500-1000 mcg/day (sublingual or IM monthly)

**RYGB, BPD/DS** (Additional)
- **Iron**: 45-60 mg/day (women, menstruating)
- **Thiamine**: 50 mg/day
- **Fat-Soluble Vitamins**: A, D, E, K (especially BPD/DS)

**Monitoring**
- **Labs**: Every 3-6 months first year, then annually
- **Check**: CBC, CMP, iron studies, B12, folate, vitamin D, PTH, vitamin A (malabsorptive)

### Complications

#### Early Complications (0-30 days)

**Leak** (1-3%)
- **Most Serious**: Sleeve (angle of His or GE junction), RYGB (gastrojejunostomy)
- **Presentation**: Tachycardia >120, fever, abdominal pain (may be subtle)
- **Diagnosis**: CT, upper GI series
- **Management**:
  - Small, contained: NPO, antibiotics, drainage
  - Large, unstable: Reoperation, washout, drain placement, feeding access
  - Endoscopic stenting: Selected cases

**Bleeding** (1-4%)
- **Staple Line**, **Mesentery**, **Trocar Sites**
- **Intraluminal**: May present with melena/hematemesis
- **Management**: Transfusion, endoscopy (clip or cautery), reoperation if unstable

**Venous Thromboembolism (VTE)** (0.5-2%)
- **DVT/PE**: High-risk population
- **Prevention**: Early mobilization, pharmacologic prophylaxis, SCDs
- **Management**: Anticoagulation

**Rhabdomyolysis** (<1%)
- **Risk**: Super-obesity, prolonged operative time, positioning
- **Monitor**: CPK, renal function
- **Management**: Aggressive hydration

#### Late Complications

**Stricture** (2-5% RYGB)
- **Location**: Gastrojejunostomy
- **Presentation**: Dysphagia, vomiting
- **Management**: Endoscopic balloon dilation (may need multiple)

**Marginal Ulcer** (5-15% RYGB)
- **Location**: Jejunal side of gastrojejunostomy
- **Risk Factors**: NSAIDs, smoking, H. pylori, large pouch
- **Presentation**: Abdominal pain, bleeding
- **Management**: PPI, H. pylori treatment, avoid NSAIDs/smoking
- **Complications**: Perforation, bleeding, gastrogastric fistula

**Internal Hernia** (1-5% RYGB)
- **Locations**: Petersen's space, mesenteric defects, transverse mesocolon
- **Presentation**: Intermittent abdominal pain, obstruction
- **Diagnosis**: CT (swirl sign, mesenteric vessels congestion)
- **Management**: Surgical reduction, close defects
- **Prevention**: Close all mesenteric defects

**Dumping Syndrome** (RYGB, ~20%)
- **Early** (30 minutes post-meal): Rapid gastric emptying, osmotic fluid shift
  - Symptoms: Nausea, cramping, diarrhea, tachycardia, hypotension
- **Late** (1-3 hours post-meal): Reactive hypoglycemia
  - Symptoms: Shakiness, sweating, confusion
- **Management**: Dietary modification (avoid simple sugars, small frequent meals)

**Nutritional Deficiencies**
- **Iron**: Anemia (especially menstruating women)
- **Vitamin B12**: Neurologic symptoms
- **Thiamine**: Beriberi, Wernicke's encephalopathy (rare but serious)
- **Calcium/Vitamin D**: Osteoporosis, fractures
- **Protein**: Malnutrition (severe cases, malabsorptive procedures)

**Weight Regain**
- **Incidence**: Variable, 10-30% regain significant weight
- **Factors**: Dietary noncompliance, insufficient follow-up, anatomic issues (pouch dilation)
- **Management**: Behavioral modification, revisional surgery (selected cases)

**Gallstones** (30-40% first year)
- **Rapid Weight Loss**: Bile supersaturation
- **Prevention**: Ursodeoxycholic acid (UDCA) first 6 months
- **Management**: Cholecystectomy if symptomatic

### Outcomes

#### Weight Loss

**Total Weight Loss (TWL) or Excess Weight Loss (EWL) at 1-2 Years**
- **Sleeve Gastrectomy**: 60-70% EWL, 25-30% TWL
- **Roux-en-Y Gastric Bypass**: 65-75% EWL, 30-35% TWL
- **BPD/DS**: 70-80% EWL, 35-40% TWL
- **Gastric Banding**: 40-50% EWL (declining use)

**Long-term** (5-10 years)
- Some weight regain expected (10-20% of lost weight)
- Maintained weight loss still significant

#### Metabolic Outcomes

**Type 2 Diabetes Remission**
- **RYGB**: 75-85% remission
- **Sleeve**: 60-70% remission
- **BPD/DS**: >90% remission
- Superior to medical management

**Hypertension**
- **Improvement**: 70-80%
- **Resolution**: 50-60%

**Dyslipidemia**
- **Improvement**: 80-90%

**Obstructive Sleep Apnea**
- **Improvement/Resolution**: 75-85%

**NASH**
- Significant improvement in liver histology

#### Quality of Life
- Significant improvement in physical function, mental health
- Improved body image, self-esteem
- Reduced joint pain, mobility issues
- Enhanced social interactions, employment opportunities

#### Mortality Reduction
- **Long-term Mortality**: 30-40% reduction compared to non-surgical controls
- Reduced cardiovascular mortality
- Reduced cancer mortality

## Key Points

### Colorectal Cancer Surgery
- **Complete mesocolic excision (CME)** for colon cancer and **total mesorectal excision (TME)** for rectal cancer improve oncologic outcomes
- **Minimum 12 lymph nodes** required for adequate staging
- **Neoadjuvant chemoradiation** standard for T3+, node-positive rectal cancer
- **MRI with rectal protocol** essential for rectal cancer staging and treatment planning
- **ERAS protocols** reduce hospital stay and complications without compromising safety
- **Laparoscopic approach** offers equivalent oncologic outcomes with improved recovery
- **Protective diverting ileostomy** for low pelvic anastomoses reduces clinical impact of leaks

### Bariatric Surgery
- **Sleeve gastrectomy** most common procedure (60-70%), excellent weight loss with lower nutritional risk than RYGB
- **RYGB** offers superior diabetes remission but higher nutritional deficiency risk
- **Multidisciplinary evaluation** essential: surgical, medical, nutritional, psychological
- **Lifelong vitamin/mineral supplementation** mandatory for all bariatric procedures
- **DVT prophylaxis** critical in high-risk population
- **Tachycardia** may be only sign of leak in early postoperative period
- **Close mesenteric defects** during RYGB to prevent internal hernias
- **Bariatric surgery reduces long-term mortality** by 30-40% compared to medical management

## References

1. **NCCN Clinical Practice Guidelines in Oncology: Colon Cancer** (Version 2.2024) and **Rectal Cancer** (Version 3.2024). National Comprehensive Cancer Network.

2. Heald RJ, et al. **The Mesorectum in Rectal Cancer Surgery - The Clue to Pelvic Recurrence?** Br J Surg. 1982;69(10):613-616. (Original TME description)

3. Fleshman J, et al. **Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes (ACOSOG Z6051)**. JAMA. 2015;314(13):1346-1355.

4. Gustafsson UO, et al. **Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations (2018)**. World J Surg. 2019;43(3):659-695.

5. Kiran RP, et al. **Combined Preoperative Mechanical Bowel Preparation with Oral Antibiotics Significantly Reduces Surgical Site Infection, Anastomotic Leak, and Ileus After Colorectal Surgery**. Ann Surg. 2015;262(3):416-425.

6. **Mechanick JI, et al. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures** - 2019 Update (ASMBS/IFSO). Surg Obes Relat Dis. 2020;16(2):175-247.

7. Schauer PR, et al. **Bariatric Surgery versus Intensive Medical Therapy for Diabetes** (STAMPEDE Trial). N Engl J Med. 2017;376(7):641-651.

8. Sjöström L, et al. **Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects** (SOS Study). N Engl J Med. 2007;357(8):741-752.

9. Peterli R, et al. **Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity (SM-BOSS Trial)**. JAMA. 2018;319(3):255-265.

10. **SAGES Guidelines**: Laparoscopic Resection for Colon Cancer (2021), Bariatric Surgery (2022). Society of American Gastrointestinal and Endoscopic Surgeons.
